Tuesday, 20 August 2019
Latest news
Main » Most Active Volume Stock: Gilead Sciences Inc. (GILD)

Most Active Volume Stock: Gilead Sciences Inc. (GILD)

12 September 2017

The Miracle Mile Advisors Llc holds 2,582 shares with $2.88M value, down from 2,964 last quarter. Gilead Sciences, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Executive Chairman Martin John C has sold 73,333 shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.76% on Monday, reaching $84.45. About 2.18 million shares traded.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, November 1st. It has underperformed by 38.50% the S&P500.

The stock of Concert Pharmaceuticals Inc (NASDAQ:CNCE) is a huge mover today! BlackRock MuniYield Pennsylvania Insured (MPA) has declined 5.94% since September 11, 2016 and is downtrending. This represents a $1.88 dividend on an annualized basis and a yield of 2.68%.

Since March 30, 2017, it had 0 buys, and 7 sales for $16.39 million activity. (NASDAQ:GILD). At the time of writing, the First Call consensus price target for the company is $81.33. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company's stock, valued at $227,197,799. (NASDAQ:GILD) for 568,562 shares.

Investors sentiment increased to 0.93 in Q4 2016. Its down 0.23, from 0.93 in 2016Q3.

These funds have shifted positions in (GILD). Its down 28.99% from 1.17 million shares previously. Blue Edge Limited Liability Com owns 10,235 shares. Fiera Capital Corp, a Quebec - Canada-based fund reported 208,853 shares. 19,816 are held by Balyasny Asset Mngmt Lc. (NASDAQ:GILD). The Michigan-based Comerica Commercial Bank has invested 0.27% in Gilead Sciences, Inc.

Yhb Investment Advisors Inc increased Dish Network Corp (NASDAQ:DISH) stake by 22,170 shares to 62,945 valued at $3.65M in 2016Q4. Wilsey Asset Management Inc.'s holdings in Gilead Sciences were worth $8,495,000 at the end of the most recent quarter. (NASDAQ:GILD). Lowe Brockenbrough & Co holds 0.23% or 19,395 shares. Oppenheimer & Communications Inc reported 2.22% stake. (NASDAQ:GILD). The California-based Hennessy Advsr has invested 0.04% in Gilead Sciences, Inc. (NASDAQ:GILD) for 3,851 shares. Laurel Grove Cap Limited Liability Company has 0.61% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 93,850 shares. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company's stock worth $1,110,228,000 after purchasing an additional 4,556,901 shares during the period. FMR LLC grew its position in Gilead Sciences by 1.1% during the 2nd quarter. Glg Partners Lp, a United Kingdom-based fund reported 448,520 shares. Jpmorgan Chase & Co (NYSE:JPM) was raised too. Vetr upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $89.27 target price for the company in a report on Wednesday, September 6th. Therefore 63% are positive.

Gilead Sciences Inc. on 6/29/2017 reported its EPS as $2.75 with the analysts projecting the EPS of the stock as $2.86. The company was maintained on Wednesday, September 23 by Societe Generale. As per Wednesday, July 29, the company rating was maintained by RBC Capital Markets. Monarch Capital Management Inc. lifted its stake in shares of Gilead Sciences by 5.9% in the 2nd quarter. The rating was initiated by William Blair on Thursday, August 31 with "Buy". The company was maintained on Friday, February 26 by Societe Generale. The rating was initiated by Berenberg on Thursday, September 22 with "Buy". Cowen & Co maintained the stock with "Buy" rating in Tuesday, May 30 report.

Concert Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company. The company has market cap of $126.30 million. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. It now has negative earnings. The Firm develops, licenses, and supports a range of software products, services and devices.

Investors sentiment decreased to 0.2 in 2016 Q4. Its up 0.08, from 1.05 in 2016Q3. It fall, as 5 investors sold Aareal Bank AG shares while 1 reduced holdings. State Street reported 60.45 million shares or 0.41% of all its holdings. West Oak Capital LLC lifted its position in Gilead Sciences by 0.7% in the 2nd quarter. First Utd Natl Bank Trust has 7,358 shares. Mutual Insurance Federation Of Agricultural Cooperatives accumulated 0.05% or 32,000 shares. Acadian Asset Management Ltd Company holds 0% or 8,482 shares in its portfolio.

Shares of Gilead Sciences, Inc. Blackrock Fund Advsrs has invested 0% of its portfolio in Concert Pharmaceuticals Inc (NASDAQ:CNCE). The SEC filing shows that Alton Gregg H performed a sale of 25,000 shares. Pinnacle Limited accumulated 299,805 shares. Principal Finance Gru holds 0.31% or 3.39M shares in its portfolio. Retail Bank Of New York Mellon reported 27.84 million shares stake.

Among 8 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 7 have Buy rating, 0 Sell and 1 Hold.

Several equities analysts have recently commented on the stock. The stock has "Buy" rating by Maxim Group on Friday, February 12. The firm has "Hold" rating by BMO Capital Markets given on Monday, August 28. Aegis Capital has "Buy" rating and $2500 target. In terms of the stock price in relation to its moving averages, company shares are 9.85% away from the 20-day moving average and 13.76% off of the 50-day average. The firm has "Hold" rating given on Tuesday, September 5 by Credit Suisse. As per Monday, November 9, the company rating was downgraded by UBS. They issued a "buy" rating and a $79.00 price objective on the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Most Active Volume Stock: Gilead Sciences Inc. (GILD)